Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-02-25
2008-08-05
Belyavskyi, Michail A (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900, C435S810000, C514S885000
Reexamination Certificate
active
07408039
ABSTRACT:
The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5484612 (1996-01-01), Brown
patent: 5635156 (1997-06-01), Ildstad
patent: 5730979 (1998-03-01), Bazin et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: WO 89/04168 (1989-05-01), None
patent: WO 93/13785 (1993-07-01), None
patent: WO 94/20619 (1994-09-01), None
patent: WO 95/03062 (1995-02-01), None
patent: WO 95/11692 (1995-05-01), None
patent: WO 95/26740 (1995-10-01), None
patent: WO 96/06165 (1996-02-01), None
patent: WO 97/41863 (1997-11-01), None
patent: WO 98/20932 (1998-05-01), None
Maraninchi et al. Lancet, 1987, vol. 2 pp. 175-178.
Atkinson et al ., Bone Marrow Transplantation, 1987, 2 pages 79-84.
Aizawa, S. et al., “Graft-Versus-Leukemia Effect in MHC-Compatible and -Incompatible Allogenic Bone Marrow Transplantation of Radiation-Induced, Leukemia-Bearing Mice”,Taransplantation, 52:885-9 (1991).
Anasetti, C. et al., “Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia of Lymphoma”,The N. E. Journal of Med., 320:197-204 (1989).
Baum, C. et al., “Isolation of a candidate human hematopoietic stem-cell population”,Proc. Natl. Acad. Sci. USA, 89:2804-8 (1992).
Baurmann, H. et al., “Kinetics of the Graft-Versus-Leukemia Response After Donor Leukocyte Infusions for Relapsed Chronic Myeloid Leukemia After Allogeneic Bone Marrow Transplantation”,Blood, 92:3582-3590 (1998).
Chopra, R. et al., “Autologous Versus Allogenic Bone Marrow Transplantation for Non-Hodgkin's Lymphoma: A Case-Controlled Analysis of the European Bone Marrow Transplant Group Registry Data”,J. Clin. Onc., 10:1690-95.
Clift, R. et al., “Histoincompatible Bone Marrow Transplants in Humans”,Ann. Rev. Immunol., 5:43-64 (1987).
Emerson, S., “Ex Vivo Expansion of Hematopoietic Prcursors, Progenitors, and Stem Cells: The Next Generation of Cellular Therapeutics”,Blood, 87:3082-88 (1996).
Fleischhauer, K. et al., Bone Marrow-Allograft Rejection by T Lymphocytes Recognizing a Single Amino Acid Difference in HLA-B44 (1990).
Giralt, S. et al., Engraftment of Allogeneic Homeopoietic Progenitor Cells with Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia without Myeloablative Therapy,Blood, 89:4531-36 (1997).
Giralt, S. et al., “Induction of graft-versus-leukemia (GVL)as primar treatment of chronic myelogenous leukemia (CML)”,Blood, 90:418a (1997).
Henslee-Downey, P. et al., “Combined In Vitro and In Vivo T Lymphocyte Depletion for the Control of Graft-Versus-Host Disease Following Haploidentical Marrow Transplant”,Transplantation, 61:738-745 (1996).
Henslee-Downey, P. et al., “Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant”,Blood, 89:3864-3872 (1997).
Ilstad, S. et al., “Effect of Selective T Cell Depletion of Host and/or Donor Bone Marrow on Lymphopoietic Repopulation, Tolerance, and Graft-ve-Host Disease in Mixed Allogeneic Chimeras (B10+B10.D2−B10)”,J. Immunology, 136:28-33 (1986).
Ilstad, S. et al., “Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts”,Nature, 307:168-70 (1984).
Johnson, B. D. et al., “Delayed infusion of normal donor cells after MHC-matches bone marrow transplantation provides and antileukemia reaction without graft-versus-host disease”,Bone Marrow Transplantation, 11:329-.
Jones, R. et al., “Evidence of a Graft-Versus-Lymphoma Effect Associated With Allogeneic Bone Marrow Transplantation”,Blood, 77:649-53 (1991).
Kawai, T. et al., “Mixed Allogeneic Chimerism and Renal Allogrtft Tolerance in Cynomolgus Monkeys”,Transplantation, 59:256-62 (1995).
Khouri, I. et al., “Transplant-Lite: Induction of Graft-Versus-Malignancy Using Fludarabine-Based Nonablative Chemotherapy and Allogeneic Blood Progenitor-Cell Transplantation os Treatment for Lymphoid Malignancies”,J. Clinical Oncology, 16:2817-24 (1998).
Kolb, H. et al., “Adoptive Immunotherapy in Canine Chimeras”,Transplantation, 63:430-436 (1997).
Lansdorp, P.M. et al., “Selective Expression of CD45 Isoforms on Functional Subpopulations of CD34+Hemopoietic Cells from Human Bone Marrow”,J. Exp. Med., 172:363-66 (1990).
Lapierre, Y. et al., “The gel test: a new way to detect red cell antigen-antibody reactions”,Transfusion, 30:109-113 (1990).
Lenschow, D. et al., “Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig”,Science, 257:789-792 (1992).
Lundberg, J. et al., “Allogeneic Bone Marrow Transplantation for Relapsed and Refractory Lymphoma Using Genotypically HLA-Identical and Alternative Donors”,J. Clin. Oncol., 9:1848-59 (1991).
Mackinnon, S. et al., “Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia After Bone Marrow Transplantation: Separation of Graft-Versus Leukemia Response From Graft-Versus-Host Disease”,Blood, 86:1261-1268 (1995).
Nakao, S. et al., “Analysis of late graft failure after allogeneic bone marrow transplantation: detection of residual host cell using amplification of variable number of tandem repeats loci”,Bone Marrow Trans., 9:107-111 (1992).
Nikolic, B. et al., “Bone marrow chimerism and transplantation tolerence”,Current Opinion in Immun., 9:634-40 (1997).
Nikolic, B. et al., “Mixed Hematopoietic, Chimerism and Transplantation Tolerance”,Immun. Res., 16/3:217-28 (1997).
O, Rielly, R. J. et al., “Transplantation of Marrow Depleted T Cells b Soybean Lectin Agglutination and E-Rosette Depletion: Major Histocompatibility Complex-Related Graft Reisstance in Leukemic Transplant Recipients”,Transplantation Proceedings, 17:455-59 (1985).
Petzer, A. et al., “Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium”,Proc. Natl. Acad. Sci. USA, 93:1470-74 (1996).
Porter, D.L. et al., “Adoptive Immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia of myelodysplasia after allogeneic bone marrow transplantation”,Bone Marrow Transplantation, 18:975-.
Preffer, F., “Flow Cytometry”,Diagnostic Immunopathology, Second Edition, Raven Press, Ltd., New York, pp. 725-749 (1995).
Ratanatharathorn, V. et al., “Prospective Comparative trial of Autologous Versus Allogeneic Bone Marrow Transplantation in Patients With Non-Hodgkin's Lymphoma”,Blood, 84:1050-55 (1994).
Sato, N. et al., “Purification of Human Marrow Progenitor Cells and Demonstration of Direct Action of Macrophage Colony-Stimulating Factor on Colony-Forming Unit-Macrophage”,Blood, 78:967-74 (1991).
Schwartz, D. et al., “Startegy to Detect Chimerism in Allogeneic Bone Marrow Transplant Recipients by PCR-Amplification Fragment Length Polymorphism Analysis of Microsatellite Polymorphisms”,Vox Sanguinis, 68:139-43 (1995).
Sharabi, Y. et al., “Mixed Chimerism and Permanent Specific Transplantation Tolerance Induced By a Nonlethal Preparative Regimen”,J. Exp. Med., et al., 169:493-502 (1989).
Slavin, S. et al., “Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marro
Spitzer Thomas R.
Sykes Megan
Belyavskyi Michail A
Choate Hall & Stewart LLP
The General Hospital Corporation
LandOfFree
Kits for treatment of hematologic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kits for treatment of hematologic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kits for treatment of hematologic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4012164